Rate Video

EAU 2020 | Genomic subtyping in bladder cancer

Peter Black • 19 Jul 2020

Bladder Cancer Genitourinary Cancer

Peter Black, MD, FACS, FRCSC, of the University of British Columbia, Vancouver, Canada, explores the clinical significance of genomic subtyping in bladder cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Can atezolizumab succeed where BCG fails in bladder cancer?

Peter Black • 8 Feb 2018

Immunotherapy approaches for NMIBC

Peter Black • 19 Jul 2020

Systemic treatments for non-muscle invasive bladder cancer

Peter Black • 8 Feb 2018

Using biomarkers to identify bladder cancer patients for neoadjuvant therapy

Peter Black • 8 Feb 2018

Related Videos

Updates on MRx0518 + pembro in patients with resistance to therapy

Alex Stevenson • 27 Nov 2020

IMvigor130: patient-reported outcomes by the addition of atezolizumab to PBC in mUC

Aris Bamias • 23 Nov 2020

Treatment options for mUC following chemo-immunotherapy failure

Aris Bamias • 23 Nov 2020

Optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing?

Arlene Siefker-Radtke • 14 Oct 2020